StageSeries C | Alive
Last Raised$90M | 2 yrs ago
ESPs containing Strata Oncology
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
Companies in this market provide tests that help to determine the appropriate course of treatment for a given patient based on their genomic profile. Many solutions in this space also include a software portal that enables physicians to easily navigate the data and make decisions.
Strata Oncology named as Highflier among 13 other companies, including Tempus, Caris, and Genomenon.
Compete with Strata Oncology?
Ensure that your company and products are accurately represented on our platform.
Strata Oncology's Products & Differentiators
StrataNGS is a clinically and analytically validated tissue-based comprehensive genomic profiling (CGP) test that assesses DNA and RNA in solid tumors. The test is optimized for small tumor tissue samples to provide more patients the opportunity to benefit from precision medicine. Every test result includes microsatellite instability (MSI) and tumor mutational burden (TMB) to help inform immunotherapy decisions. StrataNGS is covered for qualifying Medicare and Medicare Advantage patients across all solid tumors.
Research containing Strata Oncology
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Strata Oncology in 4 CB Insights research briefs, most recently on Dec 20, 2022.
Apr 22, 2020The United States Of Digital Health Startups
Expert Collections containing Strata Oncology
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Strata Oncology is included in 10 Expert Collections, including Clinical Trials Tech.
Clinical Trials Tech
Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
Strata Oncology Patents
Strata Oncology has filed 2 patents.
The 3 most popular patent topics include:
- Autoimmune diseases
Molecular biology, DNA sequencing, Biotechnology, Genetics, Bioinformatics
Molecular biology, DNA sequencing, Biotechnology, Genetics, Bioinformatics
Latest Strata Oncology News
Feb 20, 2023
The Phase II trial underway is assessing Trodelvy monotherapy or combination treatment in mUC patients. Urothelial cancer is the most common type of bladder cancer. Credit: CoRus13 / commons.wikimedia.org. Gilead Sciences has reported updated positive data from three cohorts of the Phase II TROPHY-U-01 clinical trial of Trodelvy (sacituzumab govitecan-hziy) to treat patients with metastatic urothelial cancer (mUC), the most common type of bladder cancer. Based on these results, it was observed that the first-in-class, Trop-2 directed antibody-drug conjugate produced rapid, as well as durable, responses for a range of hard-to-treat types of mUC including platinum-ineligible and progressing, post-platinum mUC. The global, multi-centre, open-label, multi-cohort, single-arm Phase II trial underway is assessing Trodelvy as a monotherapy or as a combination treatment in mUC patients after progression on a platinum-based regimen and anti-PD-1/PD-L1-based immunotherapy. Cohort 1 of the trial is evaluating Trodelvy after progression on platinum-based chemotherapy and checkpoint inhibitor (CPI) therapy. The trial’s cohorts 2, 3, 4, and 5 are ongoing. In cohort 2, Trodelvy monotherapy is assessed in platinum-ineligible patients following progression on anti-PD-1/PD-L1-based immunotherapy. Cohort 3 is assessing it in rapidly progressing mUC patients who progressed after platinum-based therapy. Cohorts 4 and 5 in the trial are evaluating Trodelvy combination therapy in treatment naive mUC patients, with subjects in cohort 4 receiving cisplatin and Cohort 5 receiving cisplatin and avelumab, in addition to Trodelvy. Gilead Oncology senior vice-president, therapeutic area head Bill Grossman said: “The TROPHY-U-01 data show consistent benefit of Trodelvy across multiple types of metastatic urothelial cancer, including the most difficult-to-treat and, often times, frail patients where treatment options are still scarce. “Trodelvy has the potential to become a cornerstone treatment in metastatic urothelial cancer, and we are excited about the expected results from the ongoing Phase III TROPiCS-04 study that may serve to convert our US accelerated approval to full approval for Trodelvy to treat patients with locally advanced or metastatic urothelial cancer following a platinum-containing chemotherapy and PD-1/PD-L1 inhibitor.” Last month, Gilead Sciences partnered with Strata Oncology to provide Trodelvy for eligible cancer patients in the Strata PATH trial. Share this article
Strata Oncology Frequently Asked Questions (FAQ)
When was Strata Oncology founded?
Strata Oncology was founded in 2015.
Where is Strata Oncology's headquarters?
Strata Oncology's headquarters is located at 8192 Jackson Road, Ann Arbor.
What is Strata Oncology's latest funding round?
Strata Oncology's latest funding round is Series C.
How much did Strata Oncology raise?
Strata Oncology raised a total of $133M.
Who are the investors of Strata Oncology?
Investors of Strata Oncology include Arboretum Ventures, Renaissance Venture Capital, Merck Global Health Innovation Fund, Baird Capital Partners, Pfizer Venture Investments and 9 more.
Who are Strata Oncology's competitors?
Competitors of Strata Oncology include Notable, Caris, Tempus, Personal Genome Diagnostics, Pangea Therapeutics and 8 more.
What products does Strata Oncology offer?
Strata Oncology's products include StrataNGS and 4 more.
Who are Strata Oncology's customers?
Customers of Strata Oncology include Ochsner Health, Metro-Minnesota Community Oncology Research Consortium (MMCORC), SCL Health, Kettering Health and Kaiser Permanente.
Compare Strata Oncology to Competitors
First Ascent Biomedical provides health care solutions. It offers drug Selection, drug testing, deoxyribonucleic acid (DNA), ribonucleic acid (RNA) sequencing, and personalized cancer treatment plans. It was founded in 2018 and is based in Beaverton, Oregon.
Perthera uses AI to analyze patient medical and molecular data to enable hospitals, physicians & advocacy groups to deliver personalized cancer care. The Perthera Platform matches patients to ranked therapeutic options to improve their clinical outcomes and allows patient data access to the key segments in the Precision Oncology market. It was founded in 2012 and is based in McLean, Virginia.
Genomic Expression's mission is to save lives and to make the delivery of healthcare more effective. The company helps doctors select the best drug for their patients, by leveraging it's clinically focused RNA sequencing technology called OneRNA. OneRNA can uniquely identify and quantify more than 34,000 RNA's in one assay and is currently undergoing beta testing by pharma companies and clinicians. Preliminary data suggests that the OneRNA assay may be suitable for determining response to the novel immune therapies including the PD1 checkpoint inhibitors.
SimBioSys is developing technology for exploring the economy of tumor microenvironments. Integrating the gamut of health data available for a patient, the capabilities within the TumorScope not only provide predictions for treatment outcomes, but provide the mechanism and reason why a treatment will succeed or fail. As a first target, SimBioSys is calibrating the TumorScope for the war on breast cancer.
Imagia Canexia Health enables collaborative AI by providing outcome-based structured clinical data and federated learning capabilities across multiple sources and researchers. Imagia's Evidens Platform uses routine clinical patient data, designed to deliver care, into outcome-based structured information appropriate for AI biomarker discovery. Imagia Healthcare delivers AI clinical solutions to B2B partners, as R&D tools, digital health products, or fully regulated software-as-medical-devices validated through the ISO13485 MDSAP certified quality system.
Genecast develops cancer diagnostic products. It offers a cancer screening kit that helps to diagnose and monitor cancer through liquid biopsy using its Allele-Discriminating Priming System (ADPS) technology. The company was founded in 2016 and is based in Seoul, South Korea.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.